Celularity Inc(CELU)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Celularity Inc (CELU) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CELU at 19.7/100 on a 32-signal composite quality model, placing it at rank #2,791 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.8) and profitability (4.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Celularity Inc reports quarterly revenue of $4.1M, net income of $-24.4M. Top institutional holders of CELU by reported 13-F value include C V STARR, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. CELU trades on the Nasdaq exchange and files with the SEC under CIK 1752828. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CELU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celularity Inc directly from SEC EDGAR.